Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH 주식 보고서

시가총액: US$2.2b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Deciphera Pharmaceuticals 관리

관리 기준 확인 3/4

Deciphera Pharmaceuticals' CEO는 Steve Hoerter, Mar2019 에 임명되었습니다 의 임기는 5.25 년입니다. 총 연간 보상은 $ 6.01M, 12.3% 로 구성됩니다. 12.3% 급여 및 87.7% 보너스(회사 주식 및 옵션 포함). 는 $ 1.86M 가치에 해당하는 회사 주식의 0.084% 직접 소유합니다. 1.86M. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 9 년입니다.

주요 정보

Steve Hoerter

최고 경영자

US$6.0m

총 보상

CEO 급여 비율12.3%
CEO 임기5.3yrs
CEO 소유권0.08%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간9yrs

최근 관리 업데이트

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

CEO 보상 분석

Steve Hoerter 의 보수는 Deciphera Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$6mUS$738k

-US$195m

Sep 30 2023n/an/a

-US$194m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$703k

-US$179m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$9mUS$676k

-US$300m

Sep 30 2021n/an/a

-US$274m

Jun 30 2021n/an/a

-US$258m

Mar 31 2021n/an/a

-US$255m

Dec 31 2020US$8mUS$650k

-US$266m

Sep 30 2020n/an/a

-US$271m

Jun 30 2020n/an/a

-US$263m

Mar 31 2020n/an/a

-US$218m

Dec 31 2019US$9mUS$435k

-US$192m

Sep 30 2019n/an/a

-US$157m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$126m

Dec 31 2018US$447kn/a

-US$100m

보상 대 시장: Steve 의 총 보상 ($USD 6.01M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.67M ).

보상과 수익: 회사가 수익성이 없는 동안 Steve 의 보상이 증가했습니다.

CEO

Steve Hoerter (53 yo)

5.3yrs

테뉴어

US$6,010,712

보상

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

리더십 팀

이름위치테뉴어보상소유권
Steven Hoerter
President5.3yrsUS$6.01m0.084%
$ 1.9m
Thomas Kelly
Executive VP9.3yrsUS$2.03m0.049%
$ 1.1m
Dashyant Dhanak
Executive VP & Chief Scientific Officerless than a yearUS$3.06m0%
$ 0
Daniel Martin
Senior VP & Chief Commercial Officer5.8yrsUS$1.58m0.036%
$ 801.7k
Matthew Sherman
Executive VP & Chief Medical Officer4.7yrsUS$2.13m0.084%
$ 1.8m
Kevin Brodbeck
Senior VP & Chief Technical Officerless than a year데이터 없음데이터 없음
Jennifer Larson
Senior Vice President of Finance & Investor Relationsno data데이터 없음데이터 없음
Jeffrey Held
Senior VP & General Counsel5.3yrs데이터 없음데이터 없음
Lisa Price
Senior VP & Chief Human Resources Officer2.4yrs데이터 없음데이터 없음
Jama Pitman
Senior VP & Chief Development Officer4.3yrs데이터 없음0.040%
$ 876.3k
Margarida Duarte
Senior VP & Head of International3.3yrs데이터 없음데이터 없음
Rodrigo Soto
Senior Vice President of Clinical Development3.4yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: DCPH 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Steven Hoerter
President6.1yrsUS$6.01m0.084%
$ 1.9m
John Martin
Independent Director9.3yrsUS$388.59k0%
$ 0
Edward Benz
Independent Director7.7yrsUS$396.09k0%
$ 0
Patricia L. Allen
Independent Director7.8yrsUS$398.55k0%
$ 0
Ron Squarer
Independent Chairman4.5yrsUS$403.30k0%
$ 0
Jean-Yves Blay
Member of Scientific Advisory Board9yrs데이터 없음데이터 없음
James Bristol
Independent Director16.8yrsUS$414.77k0%
$ 0
John Condeelis
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Filip Janku
Member of Scientific Advisory Board9yrs데이터 없음데이터 없음
F. Hodi
Member of Scientific Advisory Board9yrs데이터 없음데이터 없음
Dennis Walsh
Independent Director9.3yrsUS$386.05k0.013%
$ 281.5k
John de Groot
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

9.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: DCPH 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.